Europe Frontotemporal Dementia Market By Drug Class Type (Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants, Others), By Disease Type (Frontotemporal Dementia, Primary Progressive Aphasia Others), By End User (Hospitals & Clinics, Ambulatory Surgery Centers, Others), By Country, Competition, Forecast & Opportunities, 2028
Europe frontotemporal dementia market is expected to witness significant growth during the forecast period 2024-2028. The growing prevalence of dementia, along with the growing aging population in the region, is anticipated to facilitate the growth of the market. The gradual increase in the number of new cases of dementia registered directly every year is strengthening the growth of the frontotemporal dementia market. Moreover, the rising funding provided by the government as well as by several non-profit organizations for the target disease care, support, and R&D activities to develop new drugs are the major factor propelling the growth of the market. Furthermore, the advent of novel Frontotemporal dementia therapies as well as new diagnosing biomarkers, are projected to augment the growth of the market. The rising number of clinical trials in the region is propelling the growth of the market.
Frontotemporal dementia refers to a group of uncommon brain disorders that primarily affect the frontal and temporal lobes of the brain. These areas of the brain are generally associated with personality, behavior, and language. It often begins between the age of 40 and 65.
Growing Prevalence of Dementia
The growing incidence of dementia among European people is likely to impel the growth of the market. In 2019, the occurrence of dementia in Europe was roughly 188 per 100,000 population. The growing geriatric population is more susceptible to dementia than the younger generation due to their rising age, which, in turn, is projected to propel the growth of the market. In 2019, about 45 percent of women and 30 percent of men aged 90 years and above were living with dementia in Europe. Generally, the share of women living with dementia in Europe was much higher when compared to men.
Increasing Number of Clinical Trials
There is a large number of clinical studies which are going on for frontotemporal dementia in the region, which is projected to bolster the growth of the market. There is a total of 25 clinical studies which are completed in Europe. For instance, in 2019, a clinical trial for the device named transcranial direct current stimulation (tDCS) was completed under the study name “Non-invasive Stimulation of Brain Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia.”
Recent Developments
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook